NX-1607
Advanced Solid Tumors
Key Facts
About Nurix Therapeutics
Nurix Therapeutics is focused on discovering, developing, and commercializing small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Its core DELigase platform integrates expertise in E3 ligases, ubiquitination, and medicinal chemistry to create targeted protein degraders and inhibitors. The company has established strategic collaborations with major pharmaceutical partners like Gilead and Sanofi, and is progressing a robust pipeline of drug candidates, including its lead BTK degrader NX-5948 and CBL-B inhibitor NX-1607, through clinical development.
View full company profileAbout Nurix Therapeutics
Nurix Therapeutics is focused on discovering, developing, and commercializing small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Its core DELigase platform integrates expertise in E3 ligases, ubiquitination, and medicinal chemistry to create targeted protein degraders and inhibitors. The company has established strategic collaborations with major pharmaceutical partners like Gilead and Sanofi, and is progressing a robust pipeline of drug candidates, including its lead BTK degrader NX-5948 and CBL-B inhibitor NX-1607, through clinical development.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| SHR-1701 | Jiangsu Hengrui Medicine | Phase 1 |
| BAY 1895344 | Bayer | Phase 1 |
| HS-10342 | Hansoh Pharma | Phase 1/2 |
| ANKTIVA® + M-ceNK | ImmunityBio | Phase 1 |
| DFTX-101 | Definium Therapeutics | Phase 1/2 |
| REC-617 | Recursion Pharmaceuticals | Phase 1/2 |
| ZW220 | Zymeworks | Preclinical |
| IMA402 (TCR Bispecific) | Immatics | Phase 1 |
| IMA403 (TCR Bispecific) | Immatics | Pre-clinical |
| BCA101 | Bicara Therapeutics | Phase 1 |
| AN4005 | Adlai Nortye | Preclinical |
| AN3025 | Adlai Nortye | Preclinical |